Press release
Advanced Renal Cell Carcinoma Market to Grow Positively at a Paltry CAGR During the Study Period | Exelixis, Bristol-Myers Squibb, Novartis, Pfizer, Eisai Co., Ltd, Genentech, GlaxoSmithKline, and Bayer, and others
Advanced Renal Cell Carcinoma Market
Download sample pages @ https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Advanced Renal Cell Carcinoma Overview
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer. It develops in the lining of very small tubes, or tubules, inside the kidney, which are responsible for removing waste products from the blood.
There are over a dozen sub-types of renal cell carcinoma, identified by examining the tumor under a microscope. The most common types include Clear Cell, Papillary, Chromophobe, Clear cell papillary, Collecting Duct, and Medullary.
RCC can be distinguished based on the basic cell types of the nephron from which they are derived, and in accordance with current genetic understanding:
1. Familial renal cancer
2. Clear Cell Renal Cell Carcinoma (cRCC)
3. Multilocular cystic renal cell carcinoma
4. Papillary Renal Cell Carcinoma (pRCC)
5. Chromophobe renal carcinoma
6. Carcinoma of the collecting ducts of Bellini
7. Renal medullary carcinoma
8. Renal carcinomas associated with Xp11.2 translocations/TFE3 gene fusions
9. RCC associated with neuroblastoma
10. Mucinous tubular and spindle cell carcinoma
11. Papillary adenoma of the kidney
12. Oncocytoma
13. RCC (unclassified)
cRCC and pRCC are believed to arise from the proximal tubule, whereas chromophobe RCC and renal oncocytoma are thought to originate from intercalated cells of the cortical collecting duct from the distal nephron. Carcinoma of the collecting ducts of Bellini, on the other hand, is closely related to the principal cells of the medullary collecting duct.
People with RCC typically do not experience any symptoms during the early stages of the disease. Symptoms may only become apparent as the disease progresses, and can include blood in the urine, persistent pain on one side of the lower back, a lump on the side or abdomen, general fatigue, unexplained weight loss, anemia, and others.
Advanced Renal Cell Carcinoma Epidemiological Insights
74,000 new cases of kidney cancer were diagnosed in 2019, accounting for 4.2% of all cancer diagnoses (almost double the global average).
Renal cell carcinoma (RCC) accounts for 2% of global cancer diagnoses and deaths.
The American Cancer Society's most recent estimates for kidney cancer in the United States for 2022 are-About 79,000 new cases of kidney cancer (50,290 in men and 28,710 in women) will be diagnosed.
Between 2008 and 2017, RCC rates rose by around 1% each year.
Males are slightly more affected in the case of Advanced Renal Cell Carcinoma
Request a sample report to know more about the Advanced Renal Cell Carcinoma epidemiology insights @ https://www.delveinsight.com/report-store/advanced-renal-cell-carcinoma-rcc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Leading Companies Working in the Advanced Renal Cell Carcinoma Market
Exelixis
Bristol-Myers Squibb
Novartis
Pfizer
Eisai Co., Ltd
Genentech
GlaxoSmithKline
Bayer
And others
To understand key companies related to the Advanced Renal Cell Carcinoma Market, get a snapshot of the Advanced Renal Cell Carcinoma Regulatory and Patent Analysis @ https://www.delveinsight.com/sample-request/advanced-renal-cell-carcinoma-rcc-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Scope of the Advanced Renal Cell Carcinoma Market Report
Study Period: 2019-2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), Japan]
Key Advanced Renal Cell Carcinoma Companies: Exelixis, Bristol-Myers Squibb, Novartis, Pfizer, Eisai Co., Ltd, Genentech, GlaxoSmithKline, and Bayer, and others
Therapeutic Assessment: Advanced Renal Cell Carcinoma current marketed and emerging therapies
Advanced Renal Cell Carcinoma Market Dynamics: Advanced Renal Cell Carcinoma market drivers and barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Unmet Needs, KOL's views, Analyst's views, Advanced Renal Cell Carcinoma Market Access and Reimbursement
Table of Contents
1. Advanced Renal Cell Carcinoma Market Key Insights
2. Advanced Renal Cell Carcinoma Market Report Introduction
3. Advanced Renal Cell Carcinoma Market Overview at a Glance
4. Advanced Renal Cell Carcinoma Market Executive Summary
5. Disease Background and Overview
6. Advanced Renal Cell Carcinoma Treatment and Management
7. Advanced Renal Cell Carcinoma Epidemiology and Patient Population
8. Patient Journey
9. Advanced Renal Cell Carcinoma Emerging Drugs
10. 7MM Advanced Renal Cell Carcinoma Market Analysis
11. Advanced Renal Cell Carcinoma Market Outlook
12. Potential of Current and Emerging Therapies
13. KOL Views
14. Advanced Renal Cell Carcinoma Market Drivers
15. Advanced Renal Cell Carcinoma Market Barriers
16. Unmet Needs
17. SWOT Analysis
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
Trending Reports by DelveInsight:
Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market
Contact Us
Kritika Rehani
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Advanced Renal Cell Carcinoma Market to Grow Positively at a Paltry CAGR During the Study Period | Exelixis, Bristol-Myers Squibb, Novartis, Pfizer, Eisai Co., Ltd, Genentech, GlaxoSmithKline, and Bayer, and others here
News-ID: 3634760 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Renal
Advancements in Renal Dialysis Equipment Trend: A Crucial Influence on the Renal …
What market dynamics are playing a key role in accelerating the growth of the renal dialysis equipment market?
The escalating incidence of chronic kidney disease is projected to boost the expansion of the renal dialysis equipment market. Chronic kidney disease, a term that describes the slow and progressive decline of kidney function, can ultimately result in kidney failure and other severe health conditions. This disease is linked with several risk factors…
Renal Osteodystrophy Market: An In-Depth Analysis
The Renal Osteodystrophy Market was valued at approximately USD 2.4 billion in 2023 and is projected to reach around USD 7.1 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 12.5% from 2024 to 2032.
Renal Osteodystrophy Market Overview
The Renal Osteodystrophy Market is experiencing significant growth, driven by the increasing prevalence of chronic kidney disease (CKD) and the associated bone disorders. Advancements in diagnostic techniques have enhanced early…
Shaping the Renal Dialysis Equipment Market in 2025: Advancements in Renal Dialy …
How Big Is the Renal Dialysis Equipment Market Expected to Be, and What Will Its Growth Rate Be?
In recent years, the renal dialysis equipment market has seen robust growth. It's projected to increase from $19.52 billion in 2024 to $20.92 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.2%. Factors contributing to growth in the historic period include comprehensive training and support programs, substantial research and development…
Transforming the Veterinary Renal Disease Market in 2025: Increasing Pet Ownersh …
"What Is the Expected Size and Growth Rate of the Veterinary Renal Disease Market?
The market size for veterinary kidney diseases has seen profound growth recently. It is set to expand from $15.5 billion in 2024 to $16.63 billion in 2025, with a compound annual growth rate (CAGR) of 7.3%. Several factors contributed to this growth during the historical period, including heightened initiatives to increase disease awareness, a shift in…
Renal Cancer Pipeline Outlook Report 2024
DelveInsight's, "Renal Cancer Pipeline Insight 2024" report provides comprehensive insights about 75+ Renal Cancer companies and 80+ pipeline drugs in the Renal Cancer pipeline landscape. It covers the Renal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Renal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways…
Renal Biomarker Market to register a CAGR of 7.0% by 2026: Rising Prevalence of …
Future Market Insights delivers key insights on the global renal biomarker market in a new report titled “Renal Biomarker Market: Global Industry Analysis and Opportunity Assessment, 2016–2026.” In terms of revenue, the global renal biomarker market is projected to register a healthy CAGR of 7.0% over the forecast period. In this report, Future Market Insights throws light on the various factors and trends impacting market growth over the forecast period…
